Bifidobacterium longum BB536: Japan's Most-Studied Longum Strain

← Back to articles

Bifidobacterium longum BB536 was isolated by Morinaga Milk Industry in 1969 and has been continuously studied for more than 50 years — making it one of the oldest commercially used probiotic strains in the world. Unlike many strain-level probiotics where one or two trials dominate the evidence, BB536 has been tested across roughly 70 human studies in pollen allergy, inflammatory bowel disease adjunctive therapy, immune function in older adults, and constipation. Whether the strain warrants a place in a daily routine depends entirely on which indication you are targeting.

Indication 1: Japanese Cedar Pollinosis

BB536's most distinctive evidence is in Japanese cedar (Cryptomeria japonica) pollen allergy — the single most common spring allergic condition in Japan. A 2010 RCT in 44 adults with confirmed cedar pollinosis showed that 13 weeks of yogurt fermented with BB536 reduced nasal symptom scores, eosinophil counts, and use of rescue antihistamines versus placebo. A separate trial during cedar pollen season showed reduced ocular itching and tearing. The mechanism is presumed to involve Th1/Th2 immune rebalancing via gut-associated lymphoid tissue. The trial geography is narrow — most participants are Japanese — so generalization to other seasonal allergens (ragweed, grass) is unverified.

Indication 2: Ulcerative Colitis Adjunctive Therapy

A 2011 RCT in 56 adults with mild-to-moderate ulcerative colitis showed that BB536 supplementation alongside standard 5-ASA therapy reduced Rachmilewitz Clinical Activity Index scores and stool calprotectin versus placebo over 8 weeks. The strain has been included in subsequent multi-strain UC trials with similar adjunctive signals. BB536 should not replace 5-ASA, immunomodulator, or biologic therapy in IBD — it is an adjunct with modest effect size. See the ulcerative colitis condition page.

Indication 3: Immune Function in Older Adults

Multiple Japanese RCTs in adults over 65 have shown that 12 weeks of daily Bifidobacterium longum BB536 supplementation increased fecal Bifidobacterium counts, raised serum IgA, and modestly increased NK cell activity versus placebo. A larger trial during influenza season suggested reduced incidence of febrile respiratory episodes, though the effect was driven by participants with low baseline immune markers. The strain's elderly-immune signal overlaps with B. lactis HN019. See our BB-12 / HN019 piece for the head-to-head.

Indication 4: Constipation

BB536 modestly improves stool frequency and ease of defecation in older adults with chronic constipation, with effect sizes similar to other Bifidobacterium strains. The strain is not the top constipation choice (HN019 has more focused data), but it is a reasonable option in adults already taking it for allergy or immune indications.

Dose, Form, and Practical Use

Effective trial doses cluster at 2–5 × 10⁹ CFU daily of Bifidobacterium longum BB536. The strain is available as a standalone capsule in some markets and in Morinaga-branded yogurts in Japan. As with all bifidobacteria, refrigerate per label and continue for at least 8 weeks before judging response. Combine with a fiber-rich diet to provide substrate. The strain has an excellent multi-decade safety profile. See our Akkermansia review and the broader gut health context.

Bottom Line

Bifidobacterium longum BB536 is a genuine multi-decade probiotic with the strongest evidence in Japanese cedar pollinosis, adjunctive UC therapy, and elderly immune function. The strain is one of the few probiotics with serious evidence in seasonal allergic rhinitis. Cross-allergen and cross-population data are thinner — the strain's effect outside the Japanese cedar context is plausible but unproven.